GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: ...

Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Eli Lilly and ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

On the macro front, building permits decreased by 0.7% month-on-month in December to a seasonally adjusted rate of 1.48m, ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...

Taiwan Semiconductor Manufacturing reported a 57% rise in profit on strong demand for hardware to power AI systems.

Sezzle expects to exceed its previously announced 55% revenue growth target for FY2024.,Strong Profitability,: The company ...

Michael Osso is chief executive officer of the Crohn's & Colitis Foundation. "Eli Lilly Receives FDA Approval for Crohn's Disease Treatment," at 4:40 p.m. ET, and in a subsequent update, incorrectly ...

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...

As spot Bitcoin exchange-traded funds (ETFs) mark their first anniversary and Ethereum ETFs reach the six-month milestone, ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...